Introduction {#S1}
============

Chronic kidney disease (CKD) dramatically increases the risk of cardiovascular disease (CVD), which culminates in patients with kidney failure in a 10- to 20-fold increased hazard as compared with age- and gender-matched controls ([@B12]; [@B11]). Among patients with end-stage kidney disease (ESKD), CVD is the leading cause of death and a major source of morbidity, disabilities, and hospitalizations ([@B11]). The unacceptably high CVD risk in this population is related to a high prevalence of traditional risk factors, such as hypertension and diabetes, but also to non-traditional, kidney-specific mechanisms ([@B11]). Among the latter, metabolic disturbances represent an established feature of CKD, and are independently associated with CVD morbidity and mortality in patients with ESKD ([@B10]; [@B7], [@B8]; [@B36]). It has been suggested that differences in body composition and adiposity might explain, at least in part, the altered glucose and insulin homeostasis associated with moderate to severe CKD ([@B8]).

Ectopic fat accumulation, which refers to an increased amount of lipids around and within non-adipose tissue organs such as the skeletal muscle, liver, and heart, is now recognized as a major risk factor for metabolic alterations and CVD. It results from either an inappropriate and sustained positive energy balance, leading to the spill over of energy storage from subcutaneous adipose tissue; from impaired storage of energy in fat deposits (e.g., in congenital or acquired lipodystrophies); or from defects in adipocyte metabolism ([@B35]; [@B32]; [@B29]). The development of highly sensitive imaging-based methods to quantify fat distribution, and their application to large cohorts of non-CKD individuals uncovered a strong association between ectopic fat accumulation and insulin resistance, atherogenic dyslipidemia, hypertension, and CVD ([@B24], [@B25]). In particular, decreased muscle radiation attenuation (MRA) on computed tomography reflects excessive fat deposition in the tissue and is associated with poor cardiovascular outcome ([@B6]; [@B42]; [@B17]; [@B22]; [@B47]; [@B40]).

To date, no study investigated the association between fat distribution and clinical outcomes among patients with ESKD, who are at risk for both metabolic alterations and CVD. We therefore tested the hypothesis that non-invasive quantification of fat accumulation in muscle may help identifying ESKD patients at risk for CVD. We also investigated dynamic changes and determinants of MRA in this population.

Materials and Methods {#S2}
=====================

Study Participants, Data Collection, and Outcomes {#S2.SS1}
-------------------------------------------------

The cohort included all consecutive adult ESKD individuals starting peritoneal dialysis (PD) between January 2006 and December 2015 at Saint-Luc Academic Hospital, Brussels, Belgium. Patients were followed during time on PD, until death, kidney transplantation, transfer to hemodialysis, or end of study on 31 December 2017. Only four out of 101 patients enrolled in this study were lost to follow-up. None of the relevant baseline characteristics differed between the four patients who were lost to follow-up from those who remained in the study. Time-independent variables were collected for each patient at study entry. Time-dependent variables, including parameters of fat distribution and body composition, were collected at dialysis initiation then yearly.

The primary outcome was the occurrence of at least one non-fatal CVD event during time on dialysis, including myocardial infarction or coronary revascularization; ischemic stroke, transient ischemic attack, or cerebrovascular revascularization; lower limb necrosis or peripheral arterial revascularization ([@B26]). Residual kidney function (RKF) was estimated from daily urine volume, a robust indicator of outcome in the dialysis population ([@B34]; [@B33]; [@B44]). Glucose and icodextrin exposures were quantified as previously described ([@B23]).

The study was in accordance with the World Medical Association's Declaration of Helsinki, the Belgian law related to experiments in humans dated 7 May 2004, the General Data Protection Regulation 2016/679 and the Belgian law of 30 July 2018 regarding the protection of personal data. The Ethical Review Board of Cliniques universitaires Saint-Luc and UCLouvain approved the study (approval number: 2015/10DEC/675) and waived the requirement to obtain informed consent based on the observational and retrospective design of the study. Patients for whom individual data are shown have provided written informed consent to the use of anonymized pictures or results of biological analyses.

Computed Tomography Scanning and Evaluation of Body Composition {#S2.SS2}
---------------------------------------------------------------

Body composition was assessed by secondary analysis of electronically stored CT images, obtained at dialysis start, then yearly in every patient, as part of routine clinical practice. The goal of the procedure, initiated in January 2006 for all patients starting PD, was to identify patients at risk for or with early encapsulating peritoneal sclerosis, a dramatic complication of PD ([@B23]). At the time this procedure was initiated, the limited yield of CT scan to identify patients at risk for severe peritoneal fibrosis was not established ([@B5]). Importantly, all CT scans were non-contrast enhanced, as iodine-contrast media interferes with MRA measurement ([@B3]).

The third lumbar vertebra (L3) was chosen as a standard landmark to assess parameters of body composition and fat distribution, as previously described ([@B20]). Skeletal muscle and adipose tissue were identified by the use of Hounsfield unit (HU) thresholds --29 to + 150 and −190 to −30 HUs, respectively, and quantified by the Slice-O-Matic software, version 4.3 (Tomovision, Montreal, Canada), as previously described ([@B31]; [@B21]; [@B20]). Skeletal muscle index (SMI) was calculated as the total skeletal muscle area normalized for stature---as is conventional for body composition components (cm^2^/m^2^) ([@B31]; [@B20]). Mean MRA (HU) was reported for the entire muscle area at the third lumbar vertebra ([@B21]). Values of muscle density of 31--100 HU, 0--30 HU, and −29--0 were previously defined as normal (a value defined as two standard deviations below the mean attenuation value of muscles of young healthy persons), low, or abnormal, respectively ([@B13], [@B14]). A single trained observer, blind to patient's status, analyzed all images. Reference values from a healthy population were derived from a previously reported study which applied the Slice-O-Matic software on non-contrast abdominal computed tomography images from 420 Caucasian, medically approved living kidney donor candidates ([@B43]).

Serum Levels of Uremic Retention Solutes {#S2.SS3}
----------------------------------------

Total serum levels of uremic retention solutes were assessed on serum using a highly sensitive ultra-performance liquid chromatography--tandem mass spectrometry method, as previously described ([@B9]). Briefly, sample preparation was performed with an Ostro pass-through protocol (Waters, Zellik, Belgium). Chromatographic separation was achieved on an Acquity CSHFluoroPhenyl column (50 × 2.5 mm; 1.7 μm particle size; Waters, Zellik, Belgium). The mobile phase was a gradient of 0.1% formic acid in Milli-Q water and pure methanol at a flow rate of 0.5 ml min^--1^. Total run time was 8 min. Detection was performed using a Xevo TQS tandem mass spectrometer (Waters, Zellik, Belgium), with alternated positive and negative electrospray ionization.

Statistical Analyses {#S2.SS4}
--------------------

Results are presented as means ± SD or median \[interquartile range (IQR)\] for continuous variables and as numbers and proportions for categorical variables. Age was defined at start of PD; hypertension, diabetes, and history of coronary heart disease were constructed as binary presence/absence variables. Continuous variables were expressed in their natural units without standardization. Univariate comparisons between the CVD and non-CVD groups were performed using unpaired *t*-test, or χ^2^ test, as appropriate. Time to event analyses were performed by Cox regression and competing risk survival analyses, using the Fine and Gray method to correct for competing risk outcomes. For multivariable analyses, the following pre-specified covariates were included in the model: age at dialysis start, HDL-cholesterol level, presence of hypertension and diabetes, history of coronary heart disease, body-mass index, residual urine volume, plasma level of high-sensitivity C-reactive protein, and MRA. Collinearity between variables was quantified using variance inflation factors and condition numbers. Variance inflation factors \> 10 or condition numbers \> 30 suggested excessive correlation between variables. Because collinearity diagnostics showed high condition numbers due to significant correlations between age and MRA, sensitivity analyses were performed after exclusion of the variable age. Although MRA also modestly correlated with body-mass index, condition numbers were less than 30 and, therefore, body-mass index was included in all analyses. The likelihood ratio test was also used in nested models to determine whether exclusion of variable age or body-mass index altered model performance as compared with a model with MRA alone. To avoid overfitting, we limited the number of explanatory variables to achieve a ratio of at least 20 observations per coefficient whenever possible, and validated models using shrinkage statistics ([@B2]). Linear regression analysis using a random intercept mixed model was used to evaluate the determinants of MRA, and the effect of time on dialysis on the parameters of body composition. Time on PD was defined as a yearly discrete period in the linear regression models. A Wilcoxon matched-pairs signed rank test was used to compare estimated glomerular filtration rate and MRA before and after transplantation in a small subset of patients. All statistical analyses were performed using GraphPad Prism (version 7.0) or Stata (version 15.0) software. All tests were two-tailed and a *P*-value \< 0.05 was considered significant.

Results {#S3}
=======

Patients and Outcomes {#S3.SS1}
---------------------

The cohort ([Table 1](#T1){ref-type="table"}) included 101 patients, mostly of Caucasian origin, aged (±SD) 56 (±18) years, with a male-to-female ratio of 2.0, and a body mass index of 25.3 (±4.7) kg/m^2^. Thirty-one percent had diabetes; 81%, hypertension; 12%, coronary heart disease; and 96%, RKF at dialysis start, with a mean daily urine output of 1539 (±695) ml. Eighty-five percent received angiotensin converting enzyme inhibitors or angiotensin receptor blockers; 57%, statins; and 19% and 7%, insulin and oral antidiabetic agents, respectively. A total of 215 CT scans performed at dialysis start (median time on dialysis \[IQR\] of 33.5 days \[6--76\]) and during therapy were analyzed ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). Parameters of body composition included subcutaneous and visceral fat area (SFA and VFA), SMI, and MRA---an established surrogate for ectopic fat deposition in muscle, also termed myosteatosis ([@B13]; [@B31]; [@B21]; [@B20]). At baseline, mean SFA was 143 (±88) cm^2^; VFA, 118 (±86) cm^2^; and SMI 51 (±9) cm^2^/m^2^, and MRA 36 (±12) HUs ([Table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics.

  Characteristic                             Cohort *n* = 101   No CVD event *n* = 67   ≥1 CVD event *n* = 34   *P-*value
  ------------------------------------------ ------------------ ----------------------- ----------------------- -----------
  Female gender---*n* (%)                    34 (34)            21 (31)                 13 (38)                 0.5
  Age at ESKD---years                        56 ± 18            53 ± 19                 62 ± 13                 0.004
  Ethnicity---*n* (%)                                                                                           0.4
  Caucasian                                  94 (93)            62 (93)                 32 (94)                 
  Asian                                      3 (3)              3 (4)                   0 (0)                   
  African                                    4 (4)              2 (3)                   2 (6)                   
  Cause of ESKD---*n* (%)                                                                                       0.003
  Glomerulonephritis                         35 (35)            28 (42)                 7 (21)                  
  Diabetic nephropathy                       19 (19)            5 (7)                   14 (41)                 
  Interstitial nephritis                     10 (10)            7 (10)                  3 (9)                   
  Hypertension/renal vascular disease        10 (10)            6 (8)                   4 (12)                  
  Polycystic kidney disease                  6 (6)              3 (5)                   3 (9)                   
  Miscellaneous/unknown                      21 (20)            18 (27)                 3 (8)                   
  Charlson comorbidity index                 5.6 ± 2.6          5.2 ± 2.7               6.3 ± 2.3               0.03
  Davies comorbidity index                   1.5 ± 1.2          1.3 ± 1.1               2.1 ± 1.3               0.002
  Hypertension---*n* (%)                     82 (81)            50 (74)                 32 (94)                 0.02
  Diabetes---*n* (%)                         31 (31)            13 (19)                 18 (53)                 0.001
  History of CHF---*n* (%)                   7 (7)              5 (7)                   2 (6)                   0.8
  History of CHD---*n* (%)                   12 (12)            5 (7)                   7 (21)                  0.05
  Kidney transplant waiting list---*n* (%)   60 (59)            44 (66)                 16 (47)                 0.07
  Drug therapy                                                                                                  
  ACEi---*n* (%)                             50 (50)            29 (43)                 21 (62)                 0.08
  ARB---*n* (%)                              35 (35)            22 (33)                 13 (38)                 0.6
  Beta-blockers---*n* (%)                    39 (39)            21 (31)                 18 (53)                 0.04
  Corticosteroids---*n* (%)                  15 (15)            8 (12)                  7 (21)                  0.3
  Statins---*n* (%)                          58 (57)            33 (49)                 25 (74)                 0.02
  Oral antidiabetic agent---*n* (%)          7 (7)              4 (6)                   3 (9)                   0.6
  Insulin---*n* (%)                          19 (19)            6 (9)                   13 (38)                 \<0.001
  Body mass index---kg/m^2^                  25.3 ± 4.7         24 ± 4                  27 ± 5                  0.003
  Systolic BP---mmHg                         140 ± 25           140 ± 27                140 ± 22                0.9
  Diastolic BP---mmHg                        82 ± 14            82 ± 15                 82 ± 12                 0.9
  Plasma hsCRP---mg/dL                       2.2 ± 3.9          1.6 ± 2.8               3.4 ± 5.3               0.04
  HDL-cholesterol---mg/dL                    47 ± 16            48 ± 17                 45 ± 15                 0.4
  Triglycerides---mg/dL                      159 ± 89           165 ± 96                148 ± 77                0.4
  Residual kidney function---*n* (%)         97 (96)            65 (97)                 32 (94)                 0.5
  Residual urine volume---mL/day             1539 ± 695         1542 ± 682              1534 ± 733              0.9
  Parameters of peritoneal transport                                                                            
  Net UF 3.86% glucose---mL/4 h              494 ± 339          507 ± 297               464 ± 431               0.7
  D/P~creat~ at 4 h                          0.77 ± 0.09        0.77 ± 0.10             0.79 ± 0.08             0.5
  Albumin loss---mg/4 h                      1095 ± 446         1083 ± 507              1114 ± 339              0.5
  Automated PD---*n* (%)                     56 (55)            27 (40)                 18 (53)                 0.2
  Fat distribution and body composition                                                                         
  Subcutaneous fat area---cm^2^              143 ± 88           132 ± 72                166 ± 114               0.4
  Visceral fat area---cm^2^                  118 ± 86           109 ± 79                140 ± 96                0.2
  Skeletal muscle index---cm^2^              51 ± 9             51 ± 9                  51 ± 8                  0.9
  Muscle radiation attenuation---HU          36 ± 12            38 ± 12                 31 ± 11                 0.006

Results are presented as mean ± SD or number (

n

) and percentage (%) as appropriate. CVD, cardiovascular disease; CHF, congestive heart failure; CHD, coronary heart disease; ACEi, angiotensin-converting-enzyme inhibitors; ARB, angiotensin II receptor blockers; BP, blood pressure; hsCRP, high-sensitivity C-reactive protein; HDL, high density lipoprotein; UF, ultrafiltration; D/P

creat

, dialysate-over-plasma creatinine ratio; PD, peritoneal dialysis; HU, Hounsfield units.

Patients were followed on PD until death, transplantation, transfer to hemodialysis, or end of study period. After a median of 21 months on dialysis, 31% of patients had received a kidney transplant; 31% had been transferred to hemodialysis; 22% had died; 12% were still on PD; and 5% had been lost to follow-up or experienced recovery of kidney function. During follow-up, 34 patients presented 58 CVD events ([Supplementary Table S2](#TS1){ref-type="supplementary-material"}), including lower limb necrosis or revascularization (50%), myocardial infarction or revascularization (29%), and stroke or transient ischemic attack (21%).

Patients with CVD events during follow-up were significantly older; had a higher comorbidity index, and higher plasma levels of C-reactive protein; they were more likely to have hypertension, diabetes, or a history of coronary heart disease, than those who did not develop CVD ([Table 1](#T1){ref-type="table"}). Patients with CVD during follow-up also had lower baseline values of MRA (reflecting excessive fat deposition in muscle) than patients without CVD (31 ± 11 *vs.* 38 ± 12 HU; *P* = 0.006) ([Figure 1](#F1){ref-type="fig"}).

![Fat distribution and the risk of CVD events in patients with kidney failure. Representative images of CT scan of the abdomen and analysis of fat distribution and muscle radiation attenuation (MRA) obtained at dialysis initiation from three male patients, matched for age, body-mass index, and residual urine volume. Age at CT scan was 52, 49, and 52-year-old; and body-mass index, 20.0, 21.4, and 19.4 kg/m^2^, for patients 1, 2, and 3, respectively. Urine output was \> 1000 ml/day in all three patients. Despite similar clinical characteristics, mean MRA was 50.4, 50.9, and 22.7 HU, in patients 1, 2, and 3, respectively. Patient 3 presented cardiovascular disease (CVD) events during follow-up, in contrast to patients 1 and 2, who did not.](fphys-11-00130-g001){#F1}

Fat Accumulation in Skeletal Muscle Is Independently Associated With CVD in Kidney Failure {#S3.SS2}
------------------------------------------------------------------------------------------

Based on the strong association between MRA and CVD observed in non-CKD individuals ([@B6]; [@B42]; [@B17]; [@B22]; [@B47]; [@B40]), we tested whether baseline MRA reliably identifies patients with kidney failure at risk for subsequent CVD.

Survival analyses using Cox regressions identified higher baseline MRA (reflecting lower amounts of fat in skeletal muscle) as a strong negative predictor of CVD events during follow-up (unadjusted hazard ratio, 0.94; 95% confidence interval, 0.91--0.98, *P* = 0.004) ([Table 2](#T2){ref-type="table"}). The association was hardly changed after adjustment for additional risk factors (adjusted hazard ratio, 0.91; 95% confidence interval, 0.86--0.97, *P* = 0.006), or in sensitivity analyses ([Table 2](#T2){ref-type="table"} and [Supplementary Tables S3](#TS1){ref-type="supplementary-material"}, [S4](#TS1){ref-type="supplementary-material"}). The use of a competing risk survival model considering transfer to hemodialysis and transplantation confirmed the association between low values of MRA at baseline and an increased hazard of CVD in the dialysis population (competing risks hazard ratio, 0.95; 95% confidence interval, 0.92--0.99, *P* = 0.007).

###### 

Cox proportional hazard ratios for the time to first CVD event based on traditional risk factors and MRA at dialysis start.

                              Unadjusted   Adjusted\*                                   
  --------------------------- ------------ ------------- --------- ------ ------------- -------
  Age---years                 1.03         1.01, 1.05    0.008     0.99   0.95, 1.03    0.6
  HDL-cholesterol---mg/dL     0.99         0.97, 1.01    0.2       0.98   0.95, 1.01    0.2
  Hypertension                4.77         1.14, 19.94   0.03      7.46   1.36, 40.87   0.02
  Diabetes                    3.02         1.53, 5.99    0.002     2.31   0.85, 6.27    0.1
  CHD history                 2.79         1.21, 6.42    0.02      2.01   0.61, 6.59    0.3
  Body-mass index---kg/m^2^   1.09         1.02, 1.15    0.005     0.90   0.79, 1.02    0.09
  Urine volume---mL           1.00         1.00, 1.00    0.9       1.00   1.00, 1.00    0.05
  Plasma hsCRP---mg/dL        1.12         1.05, 1.19    \<0.001   1.18   1.06, 1.32    0.003
  MRA---HU                    0.94         0.91, 0.98    0.004     0.91   0.86, 0.97    0.006

\*Adjusted HR was calculated by integrating age, HDL-cholesterol, hypertension, diabetes, CHD history, body-mass index, residual urine volume, plasma hsCRP, and MRA. Log likelihood = -70.66. HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease; HDL, high density lipoprotein; CHD, coronary heart disease; hsCRP, high-sensitivity C-reactive protein; MRA, muscle radiation attenuation; HU, Hounsfield units.

Thus, low values of MRA at dialysis initiation represent a valuable and non-invasive indicator of increased risk of CVD in patients with kidney failure, independently of traditional risk factors.

Fat Deposits Accumulate in Muscle During Time on Dialysis, and Are Independently Associated With Low Residual Urine Volume {#S3.SS3}
--------------------------------------------------------------------------------------------------------------------------

To assess the dynamic changes in MRA over time on dialysis, we took advantage of the availability of a longitudinal follow-up of fat distribution, with CT scans performed yearly during time on PD. Considering repeated measures, we observed a significant decline in MRA over time, with a 6 and 17% decrease *vs.* baseline, at 12 and 24 months, respectively ([Figures 2A,B](#F2){ref-type="fig"} and [Supplementary Tables S1](#TS1){ref-type="supplementary-material"}, [S5](#TS1){ref-type="supplementary-material"}). Other parameters of fat distribution were not influenced by time on dialysis ([Supplementary Tables S1](#TS1){ref-type="supplementary-material"}, [S5](#TS1){ref-type="supplementary-material"}).

![Longitudinal changes in muscle radiation attenuation during time on dialysis. **(A)** Individual changes (gray thin lines) and mean values (red thick line) of MRA during time on dialysis. **(B)** Mean (± SD) values of MRA during the first, second, and third years on dialysis (\**P* = 0.03 for linear trend, one-way ANOVA). **(C,D)** Illustrative longitudinal data of fat distribution, residual kidney function, and serum p-cresyl sulfate levels from two individuals on long-term PD: a 39-year-old woman on PD for 4 years (patient 1) and a 66-year-old man on PD for 5 years (patient 2). In both patients, a significant decrease in mean MRA (from 37.0 to 24.0 HU in patient 1 and from 37.6 to 27.2 HU in patient 2) paralleled the loss in residual function and accumulation of circulating p-cresyl sulfate.](fphys-11-00130-g002){#F2}

Importantly, the association between MRA and time on dialysis attenuated and even disappeared after adjustment for residual urine volume, identified as an independent determinant of MRA in ESKD ([Table 3](#T3){ref-type="table"}). Other factors independently associated with MRA included older age, female gender, and VFA. On the contrary, the degree of glucose and icodextrin exposure---a reliable estimate of carbohydrates absorbed into the organism during PD, peritoneal solute transport rate (estimated from the dialysate-over-plasma ratio of creatinine) and net ultrafiltration were not associated with MRA.

###### 

Determinants of MRA in patients with kidney failure treated with PD.

                               Univariate analysis   Multivariate analysis                                            
  ---------------------------- --------------------- ----------------------- --------- -------------- --------------- ---------
  Age---years                  --0.36                −0.46, −0.26            \<0.001   --0.20         −0.34, −0.06    0.004
  Female gender                --4.86                −9.63, −0.08            0.05      --6.60         −10.20, −3.00   \<0.001
  Diabetes                     --6.68                −11.66, −1.70           0.009     3.14           −1.26,7.54      0.2
  Charlson comorbidity index   --2.09                −2.81, −1.36            \<0.001   --0.69         −1.56,0.19      0.1
  Visceral fat area---cm^2^    --0.05                −0.07, −0.03            \<0.001   --0.05         −0.07, −0.02    \<0.001
  Serum albumin g/L            0.31                  0.03,0.59               0.03      0.24           −0.02,0.50      0.07
  Urine volume---mL            2.66×10^−3^           $$                      0.003     2.23×10^−3^    $$              0.02
  Time on dialysis                                                                                                    
  Year 1                       1.00(*ref*.)          −                       −         1.00(*ref*.)   −               −
  Year 2                       --1.84                −4.29,0.61              0.1       0.81           −1.24,2.85      0.4
  Year 3                       --4.32                −7.13, −1.51            0.003     0.22           −2.82,3.26      0.9
  Year 4                       --3.05                −6.08, −0.02            0.05      --0.27         −3.43,2.88      0.9
  Constant                                                                             45.39          33.24,57.24     \<0.001

Coeff., coefficient; CI, confidence interval.

Dynamic changes in MRA over time on dialysis and their association with low residual urine volume were illustrated by detailed monitoring of individuals on long-term dialysis. In these patients, a striking decrease in MRA paralleled the progressive decline in kidney function and the accumulation of p-cresyl sulfate, a uremic retention solute mechanistically involved in fat redistribution in experimental models of CKD ([Figures 2C,D](#F2){ref-type="fig"}) ([@B16]).

These data identified residual urine volume, age, gender, and VFA as independent determinants of MRA in patients with kidney failure. Longitudinal follow-up suggested MRA progressively decreases (fat accumulates in skeletal muscle) in parallel to declining residual urine volume in long-term PD patients.

Kidney Failure Is Reversibly Associated With Fat Accumulation Skeletal Muscle {#S3.SS4}
-----------------------------------------------------------------------------

Based on these observations, we compared values of MRA in our cohort of incident patients with kidney failure to previously reported reference values from healthy controls with normal kidney function. Irrespective of gender, age, and body-mass index, patients with ESKD consistently had lower MRA than healthy controls, supporting the hypothesis that severely altered kidney function associates with fat accumulation in skeletal muscle ([Figure 3](#F3){ref-type="fig"}).

![Relationship between muscle radiation attenuation, gender, age, and body-mass index in patients with kidney failure, and comparison with patients with normal kidney function. Relationship between MRA and age **(A)**, and MRA and body-mass index (BMI) **(B)**, among male (red) and female (blue) patients with ESKD. Regression lines between MRA and age, and MRA and BMI in patients with ESKD (continuous lines) are compared with those from reference values obtained in patients with normal kidney function (dotted lines) ([@B43]).](fphys-11-00130-g003){#F3}

Next, we examined the longitudinal changes in MRA after transplantation and restoration of kidney function. We screened medical records and identified 12 patients from this cohort (five females/seven males, mean age ± SD, 51.3 ± 14.5 years) who received a kidney transplant after dialysis, and in whom an abdominal non-contrast enhanced CT scanning was also performed after transplantation for an unrelated clinical indication. All patients received a standard immunosuppression regimen containing mycophenolate mofetil, tacrolimus, and rapidly tapered doses of corticosteroids. After a median time \[IQR\] from transplantation to CT scanning of 169 days \[82--803\], MDRD-estimated glomerular filtration rate had increased from 6 \[5--12\] to 55 \[38--76\] ml/min/1.73 m^2^ (*P* \< 0.001) ([Figure 4](#F4){ref-type="fig"}). In parallel, MRA increased in 9/12 (75%) patients, remained stable in 2/12 (17%), and slightly decreased in 1/12 (8%) ([Figure 4](#F4){ref-type="fig"}). Overall, mean (±SD) MRA increased after transplantation from 32.0 (±3.9) to 38.8 (±7.3) HU (median of differences 5.41, exact *P* = 0.009).

![Dynamic changes in muscle radiation attenuation after kidney transplantation. Changes in MDRD-estimated glomerular filtration rate (eGFR) **(A)** and MRA **(B)** after kidney transplantation. Mean (±SD) MRA increased from 32.0 (±3.9) to 38.8 (±7.3) HU after transplantation (median of differences 5.41, Wilcoxon matched-pairs signed rank test, exact *P* = 0.009). \*\**P* \< 0.01 and \*\*\**P* \< 0.001.](fphys-11-00130-g004){#F4}

Altogether, these data showed in a small number of patients that kidney transplantation is associated with a rapid increase in MRA, supporting the hypothesis that kidney failure contributes to lipid redistribution and ectopic fat deposition in skeletal muscle.

Discussion {#S4}
==========

In a cohort of incident ESKD patients, our study shows, for the first time, a strong and independent association between low values of MRA---a surrogate for ectopic fat accumulation in skeletal muscle---and an increased risk for CVD. A low MRA at dialysis initiation is a reliable predictor of CVD, independently of traditional risk factors, suggesting its potential to identify high risk ESKD patients. Several observations also suggest that ESKD may promote ectopic fat redistribution, which in turn could be reversed by restoration of kidney function.

The worldwide obesity epidemic has emerged as a major cause of insulin resistance and type 2 diabetes, and such metabolic alterations now represent the leading risk factors for CVD. Classically defined by body-mass index, overweight and obesity are heterogeneous conditions, with important inter-individual differences in risk factor profiles despite similar amounts of total body fat, including in the CKD population ([@B39]). Anthropometric measures such as waist circumference and waist-to-hip ratio and, more recently, novel imaging techniques contributed to demonstrate the critical role of regional fat distribution in the development of metabolic alterations and CVD ([@B30]; [@B19], [@B18]; [@B42]; [@B45]; [@B24], [@B25]; [@B27]; [@B41]). In the present work, ectopic fat in skeletal muscle was strongly associated with CVD, extending for the first time the key role of altered fat distribution in the pathophysiology of CVD to the population with ESKD. In this cohort, low values of MRA at dialysis initiation identified patients at risk for subsequent CVD events, and every one HU decrease in MRA was associated with a ∼5--10% increase in the probability of CVD.

The mechanisms by which ectopic fat accumulation promotes insulin resistance and CVD have only been partially elucidated ([@B35]; [@B32]; [@B24]; [@B29]). An accumulating body of evidence suggests that intramyocellular accumulation of lipid metabolites directly leads to insulin resistance, *via* defects in insulin signaling and reduced insulin-stimulated glucose-transport activity ([@B35]; [@B32]; [@B29]). Additional mechanisms underlying the association between fatty muscle infiltration and CVD have been suggested, including the release of proinflammatory adipokines from adipocytes surrounding muscle fibers; altered mitochondrial function and increased oxidative stress in skeletal muscle cells; and accelerated aging ([@B30]; [@B22]). At the systemic level, ectopic adiposity also increases circulating blood volume and pro-atherogenic inflammatory factors, contributing to cardiac wall stress, myocardial injury, and left ventricle hypertrophy and remodeling ([@B24]). As fatty muscle infiltration parallels ectopic fat accumulation in the organism, it is tempting to speculate that at least part of the association with cardiometabolic risk is mediated by fat accumulation in other organs, such as the liver or the visceral adipose tissue ([@B38]; [@B1]). In particular, lipid accumulation in the liver (non-alcoholic fatty liver disease) has been shown to promote hepatic glucose production, insulin resistance, dyslipidemia, and dysregulated hepatokine production ([@B37]).

These data also suggest that impaired kidney function is linked to ectopic fat accumulation in skeletal muscle. First, in the whole cohort, MRA strongly and independently associated with residual urine volume. Second, longitudinal monitoring of patients on dialysis showed a progressive accumulation of lipids in skeletal muscle, which paralleled kidney function decline and accumulation of uremic retention solutes. Third, as compared with a control population with normal kidney function ([@B13]; [@B43]), MRA was consistently lower among patients on dialysis, irrespective of age, gender, and body fat distribution. Lastly, successful kidney transplantation was followed by a significant increase in MRA, suggesting the reversibility of ectopic lipid accumulation in skeletal muscle after restoration of kidney function. To the best of our knowledge, these observations are the first to suggest that kidney disease *per se* is associated with ectopic fat accumulation in human skeletal muscle, independently of other covariates, including central adiposity.

These data are in line with experimental studies in rodents, in which nephron mass reduction leads to a reduction of fat depot size and ectopic lipid redistribution ([@B46]; [@B16]; [@B28]). The mechanisms by which CKD promotes ectopic fat and insulin resistance are likely multifactorial, potentially including alterations of gut microbiota, adipokines dysregulations, inflammation and oxidative stress in adipocyte cells, and increased lipolysis ([@B15]). Recent evidence demonstrated a central role for p-cresyl sulfate, a gut-derived protein-bound uremic retention solute cleared by the kidneys and poorly dialyzed by conventional techniques. Long-term administration of p-cresyl sulfate to mice was sufficient to induce the same degree of lipid redistribution and insulin resistance as did severe CKD ([@B16]). In these models, treatment with a prebiotic reducing intestinal production of p-cresyl sulfate prevented the accumulation of ectopic lipids in muscle and improved CKD-associated insulin resistance ([@B16]). In individuals on long-term PD, loss of kidney function was associated with increasing levels of uremic retention solutes, with 4- and 15-fold increases in circulating levels of total p-cresyl sulfate as compared with CKD or healthy controls, respectively. Future trials will need to test whether enhanced removal of protein-bound uremic toxins (e.g., using intensive dialysis regimens or convective therapies), prebiotics, or other pharmacological approaches efficiently reduce ectopic fat accumulation in patients with ESKD, and whether these strategies mitigate the unacceptably high risk of CVD in this population.

This original study has several strengths, including the use of the gold standard method for the evaluation of fat distribution; systematic longitudinal monitoring with non-contrast enhanced CT scans; and detailed follow-up of global and CVD outcomes in a high-risk population of patients with ESKD. The use of a technique based on the universal and highly standardized HU scale for the measurement of MRA ensures reproducibility and allows direct comparison with existing cohorts. We also acknowledge limitations, including the absence of evaluation of insulin resistance; muscle strength; hydration status; and ectopic fat accumulation in other locations, including the liver and cardiomyocytes. As with all dialysis studies, informative censoring is a potential issue. To limit potential bias due to non-random dropout of patients, we adjusted time-to-event analyses for dialysis duration and outcome after PD, and also applied a competing risk model. Concerns about the long-term consequences of repeat radiation exposure represent a potential limitation to the clinical application of CT-based techniques to assess fat distribution ([@B4]). However, the use of single slice abdominal CT at the level of the third lumbar vertebra reduces radiation dose to less than 1 mSv (unpublished data), which is at least 10 times smaller than the corresponding dose for a whole abdomen CT scan, therefore opening translational perspectives.

Conclusion {#S5}
==========

In summary, we demonstrated in a cohort of incident patients with kidney failure that MRA is associated with CVD, independently of traditional risk factors. The use of a robust and reliable technique, based on non-contrast CT scanning of the abdomen, successfully identified incident ESKD patients at risk for subsequent CVD. Our data also suggest a close relationship between CKD and ectopic fat redistribution, a finding that may potentially explain the unacceptably high burden of CVD among patients with CKD.
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